Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Arrowhead Pharmaceuticals Corp (ARWR) Misses Q1 EPS by 2c
February 9, 2018 4:00 PM ESTArrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q1 EPS of ($0.18), $0.02 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $3.51 million versus the consensus estimate of $7.27 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
... More